Postbiocare Product In-depth Analysis and Market Value Report

Search Content
Postbiocare Product In-depth Analysis and Market Value Report
October 23, 2025

I. Core Technical Mechanism: Scientific Logic of the Triple Barrier

CH-PM-003M builds a targeted stomach-nourishing solution based on the "physical-biological-immunological" triple barrier system. Its technical route is rooted in cutting-edge microbiology and mucosal repair research, upgrading from "symptomatic relief" to "root-cause repair".

1. Physical Barrier: "Pre-protective Network" for Mucosal Repair

It relies on the patented strain Lactobacillus mucilaginosus Q8. The highly active extracellular polysaccharides (mucins) secreted by Q8 form a dense biological protective film, like a "natural band-aid".

This film binds specifically to mucosal epithelial cells to form an elastic layer. It isolates gastric acid erosion, bile irritation, rough food friction, and blocks Helicobacter pylori (Hp) from adhering to and invading damaged mucosa. This isolation provides a critical "time window" for mucosal epithelial cell regeneration, laying the foundation for subsequent repair.

2. Biological Barrier: "Regulatory Center" for Microecological Balance

A dual-postbiotic synergistic formula is adopted, overcoming the strict survival requirements of traditional probiotics. Inactivated bacterial cells and their metabolites (bacteriocins, organic acids, etc.) work through two mechanisms:

  • Compete for attachment sites on the gastrointestinal mucosa to inhibit Hp colonization.

  • Reduce gastric pH via metabolites to create an acidic microenvironment, fundamentally suppressing Hp proliferation.

This method avoids the risk of drug-resistant gene transfer in live probiotics, while ensuring higher stability and safety.

3. Immunological Barrier: "Root-cause Repairer" for Mucosal Health

Centered on postbiotic components of Lactobacillus paracasei P8, it targets the key link of mucosal damage—inflammation:

  • Regulates dendritic cell and lymphocyte activity, reducing pro-inflammatory factors (e.g., TNF-α) and promoting anti-inflammatory factors (e.g., IL-10) to alleviate mucosal inflammation.

  • Activates epithelial cell proliferation signaling pathways, accelerating damaged mucosa regeneration and healing, achieving a shift from "inflammation control" to "barrier repair" for long-term immune protection.

II. Core Advantages: Differentiated Breakthroughs for Market Demand

In China’s probiotic market (projected to reach ¥137.7 billion by 2026), CH-PM-003M gains three key differentiated advantages through precise positioning:

1. Functional Positioning: From "Single Inhibition" to "Systematic Repair"

Most market products focus only on "Hp inhibition" or "flora regulation". CH-PM-003M addresses the consumer pain point—"Hp infection is always accompanied by mucosal damage"—and provides a complete solution: "isolate irritation → inhibit pathogens → repair mucosa".

It covers both Hp-infected groups (for auxiliary conditioning) and groups with gastritis/gastric mucosal damage (for repair needs), fully reaching core target users.

2. Ingredient Form: Scenario-adapted Postbiotic Upgrade

Instead of traditional live probiotics, it uses postbiotics to solve core pain points in stomach-nourishing scenarios:

  • No refrigeration required, longer shelf life, suitable for home storage and business trips.

  • Clear chemical structure, no live bacteria colonization risk, friendly to sensitive groups (elderly, children with weak immunity).

This aligns with the 2025 food health trend of "precise functionality and convenient form".

3. Dosage Form Design: Absorption Advantage of Liquid Small Molecules

A liquid small-molecule dosage form is adopted for damaged gastrointestinal tracts:

  • Unlike capsules/tablets (needing gastric disintegration), it directly and evenly covers mucosal surfaces (e.g., gastric antrum, duodenum—high-damage areas), improving bioavailability.

  • Avoids extra irritation to sensitive mucosa during disintegration, reflecting the insight that "stomach nourishing needs gentleness".

III. Market Adaptability: Matching Demand and Trends

1. Coverage of Target Groups’ Rigid Needs

  • HP-concerned groups: High HP infection rate in China. This group needs daily protection and mucosal repair after drug treatment—the product’s "inhibition + repair" function meets their core needs.

  • Mucosal damage patients: Those in gastritis/gastric ulcer recovery or taking long-term stomach-irritating drugs have clear repair needs. The "physical protective film + immunological repair" combination provides a targeted solution.

  • Sub-healthy stomach-nourishing groups: Modern factors (staying up late, irregular diet, high pressure) cause increasing gastric burning/dull pain. The "triple barrier" system meets their daily maintenance needs.

2. Alignment with Industry Core Trends

  • Ingredient upgrade: Postbiotics, as an emerging direction in probiotics, are rising rapidly with safety and stability advantages, becoming a 2025 food health growth driver. The product takes the lead in layout.

  • Demand upgrade: Consumers shift from "general-purpose" to "precision" health products. The product’s focus on "mucosal damage + Hp" aligns with the "personalized health management" trend.

  • Trust building: Uses intuitive concepts (e.g., "band-aid-like protection") to reduce consumer understanding costs; adopts compliant terms ("inhibition", "auxiliary conditioning") to balance science popularization and standardization.

IV. Compliant Promotion and Communication Strategy

1. Core Communication Proposition

Core: "Triple barrier, targeted repair of gastric mucosa. "Differentiated highlight: "Not only inhibits Hp, but also focuses on mucosal repair. "Vivid expression: "Membrane-based repair" (to lower communication thresholds)

2. Scenario-based Efficacy Communication

- For people with frequent stomach discomfort, their core demand is rapid relief of burning or dull pain. The communication focus is that liquid small molecules reach lesions directly, Q8 forms a protective film, and discomfort is relieved within 15 minutes, while medical terms such as "treating gastritis" should be avoided. - For Hp-infected people, their core demand is auxiliary inhibition plus mucosal protection. The communication focus is that dual postbiotics inhibit Hp colonization, improve the gastric microenvironment, and reduce mucosal damage, and it should be clearly stated that "cannot replace drug treatment". - For post-treatment/medication period groups (for maintenance), their core demand is gentle mucosal repair. The communication focus is that the non-irritating liquid formula, P8 alleviates inflammation and accelerates mucosal healing, and the "daily maintenance" attribute should be emphasized.

3. Trust System Construction

  • Technical endorsement: Highlight the patent status and research background of Q8/P8 strains; link postbiotics to authoritative literature conclusions in mucosal repair.

  • Experience evidence: Use "mucosal protection visualization" (e.g., in vitro simulation videos, user repair diaries) to enhance credibility.


Share:
modbg
Get The Latest Updates And Offers

Leave your email address to receive our newsletter